Legend Biotech Corp reports results for the quarter ended December 31 - Earnings Summary

• Legend Biotech Corp LEGN.OQ reported quarterly adjusted earnings of 8 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -80 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -53 cents to -13 cents per share.

• Revenue rose 134.7% to $186.52 million from a year ago; analysts expected $178.93 million.

• Legend Biotech Corp's reported EPS for the quarter was 14 cents​.

• The company reported quarterly net income of $26.28 million.

• Legend Biotech Corp shares had risen by 4.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Legend Biotech Corp is $82.00

This summary was machine generated from LSEG data March 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)